Microevolutionary models and multi-omics analysis uncover the cross-drug resistance characteristics of capreomycin-selected Mycobacterium tuberculosis.

PMID: 413623152025

Key Findings

The study identifies tlyA mutations (Gly232Asp and Trp120fs) and eis promoter variant (c.−14c>t) as key contributors to capreomycin resistance in Mycobacterium tuberculosis. Additional mutations in rpmA (Gln19Arg) and mmaA2 (Ala48Val) are linked to cross-resistance.

View on PubMed

2gene entries

5mutation entries

AMR Genes

Gene Name	Alleles	Encodes	Confers Resistance To	Organisms	Database	Validation Status
eis	1	N-acetyltransferase	Aminoglycoside	Mycobacterium tuberculosis	Reslit	-
tlyA	1	2'-O-methyltransferase	Capreomycin	Mycobacterium tuberculosis	Reslit	-

AMR Mutations

Gene	Protein Change	Nucleotide Change	Mechanism	Organism	Resistance To	Database	Validation Status
tlyA	G232D	-	loss of methylation	Mycobacterium tuberculosis	Capreomycin	Reslit	-
rpmA	Q19R	-	-	Mycobacterium tuberculosis	Capreomycin	Reslit	-
mmaA2	A48V	-	-	-	Capreomycin	Reslit

Browse Papers

Microevolutionary models and multi-omics analysis uncover the cross-drug resistance characteristics of capreomycin-selected Mycobacterium tuberculosis.

AMR Genes

AMR Mutations